Oil prices settle at lowest since June, with Brent prices below $40
End of U.S. driving season also puts pressure on crude prices
End of U.S. driving season also puts pressure on crude prices
Aurora names CCO Miguel Martin as new CEO
Gold prices end higher as traders take cues from a dollar rally and a global, tech-led stock selloff
Stock has lost one-third of its value in a little over a week, after share sales and S&P 500 index snubbing
Astronauts on the International Space Station work out two hours a day to fend off the bone and muscle loss that happens outside the pull of Earth’s gravity. But what if a drug could replace that exercise? A group of musclebound mice might hold the answer—and it could not only help astronauts that face longer and longer missions, but also people suffering from a range of diseases back on Earth.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Using gene therapy to edit embryos, sperm or eggs in order to improve health conditions in a child should not be conducted due to the unreliability of the science, as well as due to significant ethical and moral concerns.
Artificial intelligence (AI) and machine learning (ML) are enabling clinical trial sponsors to fill in the gaps when real world evidence is incomplete or inconsistent. Trials suggest it can do even more, detecting early indicators of disease, and even quantifying pain.
Shares of Amarin Corporation are down more than 3% in premarket trading after the company reported Thursday that a panel of three judges from the U.S. Court of Appeals upheld a lower court’s ruling that paved the way for generic competition for the company’s heart disease drug, Vascepa.
When Moncef Slaoui was tapped to helm Operation Warp Speed, he sought confirmation that politics would not play a role in driving certain treatments through an approval process without the proper supporting scientific data to back it up.